Amgen, Horizon Say FTC Is Reviewing Proposed $28B Merger
U.S. biotechnology company Amgen Inc. and Ireland-based drugmaker Horizon Therapeutics PLC revealed in filings with the U.S. Securities and Exchange Commission on Monday that the Federal Trade Commission is reviewing their...To view the full article, register now.
Already a subscriber? Click here to view full article